New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
06:48 EDTNBIXNeurocrine 8M share Secondary priced at $17.75
The deal size was increased to 8M shares from 7M shares. Jefferies and JPMorgan acted as joint book running managers for the offering.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
08:59 EDTNBIXLeerink views doc checks as positive for ACADIA, Neurocrine
Subscribe for More Information
08:35 EDTNBIXNeurocrine begins Phase II clinical trial for NBI-98854
Subscribe for More Information
January 28, 2016
07:12 EDTNBIXAbbVie intiates enrollment in Phase 3 clinical program for Elagolix
AbbVie (ABBV), in cooperation with Neurocrine Biosciences (NBIX), announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo. These studies are designed to assess the change in menstrual blood loss utilizing the alkaline hematin method, comparing baseline to month six of treatment. Additional secondary efficacy endpoints are being evaluated; including assessing changes in fibroid volume, monthly blood loss and hemoglobin levels. Bone mineral density will also be assessed.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use